Andreas Plückthun has been Professor of Biochemistry at the University of Zürich, Switzerland since 1993. He studied chemistry at the University of Heidelberg and received a PhD from the University of California at San Diego in 1982, was postdoctoral fellow at Harvard University (1982-85), and group leader at the Genzentrum and Max-Planck-Institut für Biochemie in Martinsried (1985-93). He has written over 400 publications, cited over 35,000 times (h-index 109). He was elected to the German Academy of Science in 2003.
He received numerous international awards, among them the 2016 Christian-Anfinsen Award of the Protein Society as "pioneer of protein engineering". He is co-founder of Morphosys AG (Martinsried, Germany), Molecular Partners AG (Zürich, Switzerland) and G7 Therapeutics, recently divested to Heptares/Sosei (Zürich, Switzerland).
His research field is protein engineering in all flavors: antibodies, novel scaffold proteins (DARPins and Armadillos), and stable membrane proteins. His laboratory combines biophysical studies, directed evolution and biomedical applications.